ArticleIJID regions2025
Molecular and serological prevalence of high-risk human papillomavirus among asymptomatic men in Georgia.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide, associated with a range of anogenital and oropharyngeal cancers in men. Despite this, male populations are often underrepresented in HPV surveillance and prevention programs, particularly in Eastern Europe and the Caucasus. This study aimed to assess the prevalence of high-risk HPV in asymptomatic men in Georgia using both serologic and molecular diagnostics. Methods: We conducted a cross-sectional study of 372 asymptomatic men aged 25-65 years, recruited from urban outpatient clinics in Tbilisi. Serum samples were analyzed using a commercial enzyme-linked immunosorbent assay kit (DiaPro) to detect immunoglobulin G antibodies specific to HPV16 and HPV18. Simultaneously, HPV DNA was extracted and genotyped using the Anyplex™ II HPV28 Detection Assay (Seegene), which identifies 28 genotypes, including 14 high-risk types. Results: Only five participants (1.34%; 95% confidence interval: 0.6-3.1%) tested positive for HPV16/18-specific immunoglobulin G antibodies. In contrast, HPV DNA was detected in 165 participants (44.4%). The most common genotypes were HPV31 (15.1%), HPV16 (10.0%), HPV33 (5.4%), and HPV18 (4.8%). All detected genotypes were high-risk. Among seropositive individuals, three had HPV16, one had HPV31, and one had HPV18. Conclusions: These findings reveal a high prevalence of high-risk HPV genotypes in asymptomatic Georgian men, despite low seropositivity. The results support the need for gender-neutral HPV vaccination and underscore the limitations of serological testing in male populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.